Arachidonic acid metabolites in pathogenic yeasts by Ruan Ells et al.
Ells et al. Lipids in Health and Disease 2012, 11:100
http://www.lipidworld.com/content/11/1/100REVIEW Open AccessArachidonic acid metabolites in
pathogenic yeasts
Ruan Ells1, Johan LF Kock1, Jacobus Albertyn1 and Carolina H Pohl1,2*Abstract
Although most of what is known about the biology and function of arachidonic acid metabolites comes from the
study of mammalian biology, these compounds can also be produced by lower eukaryotes, including yeasts and
other fungi. It is also in this group of organisms that the least is known about the metabolic pathways leading to
the production of these compounds as well as the functions of these compounds in the biology of fungi and
yeasts. This review will deal with the discovery of oxylipins from polyunsaturated fatty acids, and more specifically
the arachidonic acid derived eicosanoids, such as 3-hydroxy eicosatetraenoic acid, prostaglandin F2α and
prostaglandin E2, in yeasts starting in the early 1990s. This review will also focus on what is known about the
metabolic pathways and/or proteins involved in the production of these compounds in pathogenic yeasts. The
possible roles of these compounds in the biology, including the pathology, of these organisms will be discussed.
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Fatty acids are the main components of lipids and play a
key role as structural components of cellular membranes,
affecting the physical state of the membranes, as storage
lipids and as signaling molecules that impact the immune
system in various ways [1]. Oxylipins is the collective term
for oxygenated polyunsaturated fatty acids (PUFAs) and
metabolites and includes the eicosanoids, which are an
important group of oxygenated C20 PUFAs [2]. These
compounds represent the prostaglandins, thromboxanes,
prostacyclins, leukotrienes, lipoxins, hepoxilins, hydro
(pero)xy fatty acids, hydroxylated fatty acids and epoxy
derivatives [3,4]. In mammalian cells they are mainly
synthesized from eicosatrienoic acid [20:3(n-6), dihomo-
γ-linolenic acid (DGLA)], eicosatetraenoic acid [20:4(n-6),
arachidonic acid (AA)] and eicosapentaenoic acid [20:5
(n-3), EPA] [3] as well as from docosahexaenoic acid
[22:6(n-3), DHA] [5]. They are synthesized through the
actions of cyclooxygenases (COX) [6], lipoxygenases
(LOX) [7], cytochrome P450s (CYP450s) [4,8,9], or non-
enzymatic pathways [10]. However, in fungi the precursors
for oxylipin production are usually octadecenoic acid* Correspondence: PohlCH@ufs.ac.za
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reproduction in any medium, provided the or[18:1(n-9), oleic acid], octadecadienoic acid [18:2(n-6),
linoleic acid] and octadecatrienoic acid [18:3(n-3), lino-
lenic acid] [11].
Most of what is known about oxylipins, such as eicosa-
noids, comes from the investigation of mammalian biol-
ogy and very little is known about the biochemistry of
eicosanoid production in the lower organisms, including
yeasts. This review will focus on the occurrence of ara-
chidonic acid derived oxylipins in pathogenic yeast,
known metabolic pathways for the production of these
oxylipins as well as the possible roles and significance of
these compounds in the biology of pathogenic yeasts.Occurrence of eicosanoids in pathogenic yeasts
In the early 1990’s the presence of AA metabolites (includ-
ing prostaglandins and 3-hydroxy (OH) fatty acids) in en-
vironmental yeasts belonging to the Dipodascaceae and
Lipomycetaceae families was discovered [12-17]. Follow-
ing this discovery, AA metabolites were also implicated in
the pathogenesis of certain yeasts. Although, host
cells produce eicosanoids, the pathogen can also con-
tribute to this production. The production of a 3-OH
fatty acid from exogenous AA was found in the
pathogenic yeast, Candida albicans [18,19]. This com-
pound was identified by GC-MS as 3,18-dihydroxy-
5,8,11,14-eicosatetraenoic acid (3,18 di-HETE) and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a role in morphogenesis and pathogenicity. In bio-
films of the closely related yeast, C. dubliniensis, the
production of 3,18 di-HETE from exogenous AA was
also found [20].
Noverr and co-workers [21] indicated by the use of
ELISA assays that the pathogenic yeasts, C. albicans and
Cryptococcus neoformans, have the ability to produce
and secrete prostaglandins (PGs) de novo and that the
addition of exogenous AA increased this production sig-
nificantly. They referred to it as PGEx due to the cross-
reactivity observed with prostaglandins of the E class
using prostaglandin immunoassays. Later, using mass
spectrometry, it was verified as PGE2 [22,23]. Candida
albicans and Crypt. neoformans can also produce other
prostaglandins, including PGD2 and PGF2α as well as
leukotrienes (LTB4, cysteinyl leukotrienes) from exogen-
ous AA [24]. Similar results were obtained by Erb-
Downward and co-workers [25] in Crypt. neoformans,
however lysates from this yeast produced more PGF2α
compared to PGE2, in contrast to C. albicans, where
PGE2 was the main prostaglandin produced. This eicosa-
noid production was found for planktonic cells, however
the production of PGE2, sensitive to COX inhibitors, de
novo by C. albicans biofilms has also been reported
[26,27]. The COX inhibitors used in the latter study also
inhibited biofilm formation. Interestingly, the addition of
PGE2 together with acetylsalicylic acid (aspirin, ASA)
completely removed biofilm inhibition by ASA. The
authors concluded that biofilm development, morpho-
genesis and regulation of physiological processes in
this yeast are regulated by COX-dependent synthesis
of fungal prostaglandins.
During the last few years there has also been an increase
in other non-albicans Candida species as opportunistic
human pathogens [28]. These include C. dubliniensis,
C. glabrata, C. krusei, C. tropicalis and C. parapsilosis. Re-
cently, it was found that C. dubliniensis, C. glabrata and
C. tropicalis are also capable of producing PGE2 [29,30].
Candida albicans, C. dubliniensis and C. tropicalis pro-
duced considerable amounts of PGE2 whereas C. glabrata
produced only trace amounts. Interestingly, in the pres-
ence of human keratinocytes, important in cutaneous im-
mune responses, C. albicans, C. tropicalis as well as
C. glabrata produced 10-fold more PGE2 with the
keratinocytes alone producing only trace amounts of
PGE2. This indicates the involvement of PGE2 during
host pathogen interactions, specifically during super-
ficial infections.
The pathogenic dimorphic yeast, Paracoccidioides
brasiliensis, also produced prostaglandins from endogen-
ous and exogenous AA [31,32]. The use of COX inhibi-
tors, indomethacin and piroxicam, not only decreased
prostaglandin production but also viability of the yeast.Biosynthesis of yeast eicosanoids
The biosynthetic pathway for eicosanoid production in
mammalian cells has been well studied and is used as a
model to try and identify enzymes involved in this pathway
in lower organisms, including fungi. The specific AA meta-
bolites produced in vivo in mammalian cells are dependent
upon the most active enzymes in specific tissues [33].
Cyclooxygenases, LOX, CYP450s and β–oxidation enzymes
are known to add hydroxyl groups to AA [34].
Limited information is, however, available regarding
the mechanisms involved in eicosanoid production in
yeasts. Enzymatic involvement in these pathways was
indicated by incubating AA together with boiled lysates
of either C. albicans or Crypt. neoformans [22,23,25].
This lead to a significant reduction in PGE2 produced,
suggesting the presence of a denaturable enzymatic
pathway in these yeasts. Brodhun and Feussner [35]
speculated about the unlikelihood of the existence of a
specific prostaglandin pathway in fungi. They ascribed
these reactions to be similar to a known isoprostane type
of non-specific lipid peroxidation reaction that can be
catalyzed by any protein harboring iron as cofactor.
The use of different enzyme inhibitors is widely ap-
plied in order to identify the pathways and putative
enzymes involved in eicosanoid production by fungi.
There are a number of studies that used COX inhibitors,
including ASA and other non-steroidal anti-inflammatory
drugs (NSAIDs), as well as LOX inhibitors, to identify
possible mechanisms involved in fungal eicosanoid pro-
duction [15,25,36,37], however this has not been able to
provide conclusive evidence.
Candida albicans
Initially Noverr and co-workers [21] speculated that
COX-like enzymes had to be present in C. albicans. In
their studies they used different COX inhibitors (i.e. eto-
dolac, indomethacin and piroxicam), to evaluate prosta-
glandin production. They found that all these inhibitors
not only decreased prostaglandin production but also
decreased the viability of these cells. This suggests that
the decrease was not due to a specific inhibition of the
enzyme but rather due to an effect on cell viability or that
prostaglandin production could regulate the viability of
the yeast [22]. Later, using non-selective mammalian COX
inhibitors, ASA, indomethacin and resveratrol, and the
LOX inhibitor, nordihydroguaiaretic acid (NDGA) (also
known as a COX inhibitor) the production of PGE2 was
reduced without affecting viability [23]. Similar results
were obtained for C. albicans and C. dubliniensis bio-
films using ASA and NDGA [29]. However, the use
of the selective COX-2 inhibitor, CAY10404 [3-(4-methyl
sulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole], had
no effect on PGE2 production, suggesting that enzymes dis-
tinct from mammalian COX and LOX are responsible for
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BLAST results used to search the genomes of C. albicans
for COX and LOX homologues, which did not reveal any
sequences with significant homology to mammalian COX
and LOX [38,39]. This was followed by the identification of
two non-COX/LOX-related enzymes, involved in PGE2
production in C. albicans [23]. These enzymes were identi-
fied as a fatty acid desaturase, Ole2p, and a multicopper
oxidase or laccase homologue, Fet3p. The importance of
these enzymes was illustrated by indicating that mutants
lacking the OLE2 or FET3 gene had a reduced pro-
duction of PGE2. However, this did not completely in-
hibit PGE2 production, suggesting that other enzymes
are also involved.
Recently, the involvement of multicopper oxidases in the
production of PGE2 by both C. albicans and C. dubliniensis
biofilms, as well as the possible role of CYP450s in prosta-
glandin production, possibly upstream of the multicopper
oxidases were also indicated [29]. This was done using
different CYP450 inhibitors [6-(2-propargyloxyphenyl)
hexanoic acid and 1-aminobenzotriazole] and multicopper
oxidase inhibitors (ammonium tetrathiomolybdate and so-
dium azide). These inhibitors significantly decreased PGE2
production without affecting cell biomass and viability of
C. albicans and C. dubliniensis biofilms. The availability of
the genomes indicated the presence of 12 CYP450s in
C. albicans and 10 CYP450s in C. dubliniensis com-
pared to the only 3 in S. cerevisiae [40]. This may in-
dicate the involvement of CYP450s in pathogenesis.
Cryptococcus neoformans
Since the COX inhibitor, indomethacin, could reduce
prostaglandin production in Crypt. neoformans, it was
initially speculated that the enzyme involved was COX-
related [21]. However, similar to C. albicans, the genome
of Crypt. neoformans did not reveal any sequence hom-
ology to mammalian COX and LOX [22,25]. The study
by Erb-Downward and Huffnagle [22] did not observe
this inhibitory effect in the presence of the COX inhibi-
tors, ASA and indomethacin, suggesting that other non-
COX enzymes are involved. It must, however, be noted
that the difference in especially incubation time used in
the latter study, may have contributed to the observed
difference in results.
In another study, Erb-Downward and co-workers [25]
indicated that the polyphenolic LOX inhibitors, caffeic
acid, NDGA and resveratrol inhibited both PGE2 and
PGF2α production in Crypt. neoformans, even though a
LOX homologue is absent. This lead to the identification
of a multicopper oxidase, laccase, known to bind poly-
phenols, as an enzyme involved in prostaglandin produc-
tion in Crypt. neoformans. Laccase alone did not convert
the PGE2 precursors (AA or PGH2) to PGG2 or new
prostaglandins, but it did convert PGG2 to PGE2 and 15-keto-PGE2. This suggests that multicopper oxidases
might play a significant role in eicosanoid production by
this pathogenic yeast. However, it is not the only enzyme
involved, and questions still need to be answered regard-
ing the enzymes upstream of the multicopper oxidase.
In addition, it has been speculated that enzymes belong-
ing to the Old Yellow Enzyme family might be involved
in this pathway, leading to the production of PGF2α from
PGE2 [25].
Paracoccidioides brasiliensis
Similar to C. albicans and Crypt. neoformans, it is specu-
lated that a COX pathway is involved in the production
of prostaglandin by the dimorphic yeast, P. brasiliensis
[31,32]. This was indicated by the use of indomethacin
and piroxicam, which not only inhibited prostaglandin
production but also fungal viability. The authors suggest
a COX-dependent metabolic pathway is involved and
that, similar to C. albicans, prostaglandins have a pos-
sible role in fungal survival.
Biological activity of eicosanoids
The production of eicosanoids by mammalian cells is in
response to mechanical factors or chemical stimuli, such
as cytokines, or in response to pathogen invasion [41].
They act similar to hormones, as potent biological regu-
lators and are involved in many systems such as the car-
diovascular, renal, reproduction and the immune system
[42,43]. The immunomodulatory properties of eicosa-
noids have been studied intensively in mammalian cells
with a single eicosanoid capable of having pleiotropic
functions [41,44]. This includes different physiological
and pharmacological effects on different cell types.
These effects are mainly due to the existence of multiple
receptors for each lipid species on plasma membranes.
Eicosanoids are known to function through G-protein-
coupled receptors (GPCRs), known as guanine nucleotide
regulatory proteins, to elicit their pharmacological and sig-
naling profiles [3,44]. The activated trimeric G-proteins
affect the concentrations of the second messengers, cyclic
AMP (cAMP), or intracellular ions such as K+. This
occurs through the stimulation or inhibition of adenylate
cyclase or the opening or closing of K+ channels.
CD4+ T cells differentiate into CD4+ T helper (Th)
cells, Th1 or Th2, in response to antigens or cytokines
to eliminate pathogens [45]. These Th cells secrete dif-
ferent cytokines and have different functions during an
immune response. The Th1 cytokines are involved in ac-
tivating macrophages and cytotoxic T cells, known as
cell-mediated/protective immunity against intracellular
pathogens [46]. In addition, the Th2 cytokines are
involved in humoral immunity by helping B cells to pro-
duce antibodies. However, an imbalance in Th1/Th2
responses can be detrimental to the host, leading to
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also negatively regulate each other [47]. Interestingly,
pathogen studies suggested that eicosanoid production,
especially PGE2, could shift these Th responses in favor
of the pathogen [47,48]. Therefore, the activation of Th1
and/or Th2 responses may correlate to the occurrence
of resistance and susceptibility to infections.
Both host and pathogen are capable of producing PGE2
during an infection indicating that both can modulate im-
mune responses [48,49]. These biological effects of prosta-
glandins on the immune system and the enhanced
production of prostaglandins and leukotrienes by patho-
genic yeasts may lead to the intracellular survival followed
by chronic and disseminated infections [50]. This can be
illustrated by the ability of these eicosanoids to down-
regulate macrophage functions as mentioned above for
mammalian eicosanoids.
Candida infections stimulate both the innate and
adaptive immune responses [51-53]. Although several
studies indicated that C. albicans and Crypt. neoformans
stimulate the production of Th1-type cytokines leading
to protective immunity or acquired resistance against
these pathogens [53-57], the production of PGE2 during
infections inhibits Th1 responses and has an inducing
effect on Th2 and Th17 responses [49,58,59]. It is
known that Th1 responses are critical for protection
against candidiasis whereas Th2 responses are less import-
ant [60]. Additionally, Th2 responses are non-protective
against pathogens and lead to chronic or disseminated
infections [51]. Th17 responses play an important role in
autoimmune diseases as well as the control of fungal
infections by initiating and maintaining inflammation
[61]. Additionally, the uncontrolled production of Th17
cytokines can be harmful to the host during systemic
infections [59]. Candida albicans PGE2 enhances Th17
responses by stimulating the production of IL-17 and
IL-22. Similarly, the monocyte subset, CD14++ CD16-,
produce more PGE2 and also induces a greater Th17
response compared to the other monocyte subsets,
CD14+ CD16+, in response to C. albicans [62]. The
Th17 responses are induced by the presence of the patho-
gen associated molecular patterns, mannan and β-glucan
from C. albicans [61,63]. So the production of PGE2 dur-
ing infections might be beneficial for the pathogens.
Another important factor induced by PGE2, is tissue eo-
sinophilia, leading to tissue damage, which is a common
feature of some chronic fungal infections [49].
The PGEx (PGE2) produced by both C. albicans and
Crypt. neoformans was found to be biologically active on
both yeast and mammalian cells [21,64]. It had im-
munosuppressive effects in mammalian cells by down-
modulating chemokine production, tumor necrosis factor
alpha (TNFα) production and splenocyte proliferation
while up-regulating IL-10 production (Th2 responses).The biological activity on yeast was indicated through the
stimulation of germination in C. albicans, similar to syn-
thetic PGE2 and thromboxane B2 (TXB2) [64]. Similar
results were obtained by Kalo-Klein and Witkin [65] using
commercial PGE2, suggesting that morphogenesis (yeast-
to-hyphae transition) is induced in C. albicans by a PGE2
caused increase in cAMP levels. The increase in intracel-
lular cAMP levels in guinea-pig tracheal epithelial cells
due to commercial PGE2 was also observed [66]. However,
other prostaglandins i.e. PGI2, PGF2α and PGD2 did not
exert any effect on cAMP. Interestingly, PGF2α had no
effect on germination of C. albicans [65]. This sug-
gests that the other prostaglandins, PGI2 and PGD2,
may also not affect germination by C. albicans. The
PGE2 precursor, AA as well as other long chain fatty
acids (i.e. C18 fatty acids) did not have any effect on
germination [64].
Morphogenesis in pathogenic fungi is often associated
with increased virulence and mucosal invasiveness [67]
and the start of biofilm formation, with infections by
C. albicans mainly caused by biofilms [68]. This sug-
gests that prostaglandin production, especially PGE2,
might be an important virulence factor. However, the
exact role of prostaglandins in morphogenesis and biofilm
development is complex and remains unclear. Although,
Alem and Douglas [27] indicated the production of PGE2
by C. albicans biofilms, PGE2 did not function as a
QS molecule, with no correlation found between PGE2
production and cell density. In addition, 3,18-diHETE was
shown, through immunofluorescence microscopy using a
polyclonal antibody, specific against chemically synthe-
sized 3-OH fatty acids [69], to be mainly associated with
the hyphal forms of C. albicans and not the yeast form
[18]. This might play a role in the anchorage of these cells
to host cells during infections. This indicates that 3-OH
fatty acid production may be an important virulence factor
in C. albicans as well as in C. dubliniensis, since 3,18-
diHETE production has also been found in this closely
related yeast [20]. Interestingly, the related 3-OH AA me-
tabolite, 3R-HETE, produced by the non-pathogenic
yeast D. uninucleata, was also reported to have pro-
inflammatory actions in mammalian cells by affecting
signal transduction processes in human neutrophils
and tumor cells [70,71]. Ciccoli and co-workers [72]
also indicated that 3-HETE can be used as a substrate
for mammalian COX-2, activated by C. albicans in a HeLa
infection model [73], to produce pro-inflammatory 3-OH
PGE2. This metabolite increased inflammation in host
cells. The immunomodulatory activities of this compound
were illustrated through the increased upregulation of IL-
6 gene expression (an enhanced Th2 response), in com-
parison to PGE2, as well as cAMP levels, similar to PGE2,
in Jurkat T-cells and lung adenocarcinoma cells (A549
cells), respectively [49,72].
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This review indicates that AA metabolites are widely dis-
tributed in the fungal domain. The limited available know-
ledge about the possible pathways or enzymes involved in
fungal eicosanoid production compared to mammalian
cells, is evident. In addition, when COX and LOX inhibi-
tors are used to identify the pathways involved, it should
be noted that these inhibitors are non-selective, therefore
they could inhibit various enzymes needed for fungal via-
bility, thus leading to cell death. The so called non-
prostaglandin mediated effects by different NSAIDs have
been indicated before in mammalian cells [74]. These in-
clude the interactions of NSAIDs with biological mem-
branes and influencing important cell functions such as
transmembrane anion transport, oxidative phosphoryl-
ation, enzyme activity as well as the uptake of AA. These
mechanisms, together with the effect of ASA on the mito-
chondrial activity of various yeasts [75], might provide a
possible explanation for the observed effects in the differ-
ent studies. Additionally, some of these inhibitors used,
such as NDGA, also have antioxidative properties which
could also lead to the observed decrease in prostaglandin
production [76].
The statement that PGE2 is responsible or involved in
fungal viability should be interpreted with care. Al-
though, Alem and Douglas [26] as well as de Quadros
and co-workers [77] indicated that NSAID mediated in-
hibition of biofilm formation by C. albicans can be over-
come by the addition of PGE2, the exact role of PGE2
during C. albicans biofilm formation is still unclear and
needs further investigation.
The importance of eicosanoids during host pathogen
interactions was also emphasized. More specifically, the
immune response, the system that is responsible for pro-
tecting us against pathogens, can be altered through the
production of eicosanoids. The production of these lipid
mediators functions as components of a complex chem-
ical signaling system between host and pathogen. Add-
itionally, the effects of prostaglandins and their fatty
acid precursors might be species specific, but that it
does play an important role during pathogenesis can-
not be ignored.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CHP was responsible for the layout and initial idea for the manuscript. RE
and CHP wrote the manuscript. JLFK and JA participated in researching the
literature and critical discussion of the work. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported by the National Research Foundation, South Africa
(Grant numbers TTK2007041000014 and BS2008092300002).
Received: 19 June 2012 Accepted: 3 August 2012
Published: 8 August 2012References
1. Van Bogaert INA, Groeneboer S, Saerens K, Soetaert W: The role of
cytochrome P450 monooxygenases in microbial fatty acid metabolism.
FEBS J 2011, 278:206–221.
2. Kock JLF, Strauss CJ, Pohl CH, Nigam S: The distribution of 3-hydroxy
oxylipins in fungi. Prostag Oth Lipid M 2003, 71:85–96.
3. Smith WL: The eicosanoids and their biochemical mechanism of action.
Biochem J 1989, 259:315–324.
4. Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J Biol
Chem 2001, 276:36059–36062.
5. Serhan CN, Arita M, Hong S, Gotlinger K: Resolvins, docosatrienes, and
neuroprotectins, novel omega-3-derived mediators, and their
endogenous aspirin-triggered epimers. Lipids 2004, 39:1125–1132.
6. Murakami M, Kudo I: Recent advances in molecular biology and
physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res
2004, 43:3–35.
7. Henderson WR: The role of leukotrienes in inflammation. Ann Intern Med
1994, 121:684–697.
8. Carroll MA, McGiff JC: A new class of lipid mediators: cytochrome P450
arachidonate metabolites. Thorax 2000, 55:S13–S16.
9. Zhu Y, Schieber EB, McGiff JC, Balazy M: Identification of arachidonate
P-450 metabolites in human platelet phospholipids. Hypertension 1995,
25:854–859.
10. Buczynski MW, Dumlao DS, Dennis ED: Thematic review series:
proteomics. An integrated omics analysis of eicosanoid biology. J Lipid
Res 2009, 50:1015–1038.
11. Tsitsigiannis DI, Keller NP: Oxylipins as developmental and host-fungal
communication signals. Trends Microbiol 2007, 15:109–118.
12. Botha A, Kock JLF, van Dyk MS, Coetzee DJ, Augustyn OPH, Botes PJ:
Yeast eicosanoids. IV. Evidence for prostaglandin production during
ascosporogenesis by Dipodascopsis tóthii. System Appl Microbiol 1993,
16:159–163.
13. Coetzee DJ, Kock JLF, Botha A, van Dyk MS, Smit EJ, Botes PJ, Augustyn
OPH: The distribution of arachidonic acid metabolites in the life cycle of
Dipodascopsis uninucleata. System Appl Microbiol 1992, 15:311–318.
14. Fox SR, Hamberg M, Friend J, Ratledge C: Evidence for the mitochondrial
biosynthesis of 3R-Hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid in the
yeast Dipodascopsis uninucleata. Lipids 2000, 35:1205–1214.
15. Kock JLF, Coetzee DJ, van Dyk MS, Truscott M, Botha A, Augustyn OP:
Evidence for, and taxonomic value of, an arachidonic acid cascade in
the Lipomycetaceae. Antonie Leeuwenhoek 1992, 62:251–259.
16. Kock JLF, Coetzee DJ, van Dyk MS, Truscott M, Cloete FC, van Wyk V,
Augustyn OPH: Evidence for pharmacologically active prostaglandins in
yeasts. S Afr J Sci 1991, 87:73–75.
17. Van Dyk MS, Kock JLF, Coetzee DJ, Augustyn OPH, Nigam S: Isolation of a
novel arachidonic acid metabolite 3-hydroxy-5,8,11,14-eicosatetraenoic
acid (3-HETE) from the yeast Dipodascopsis uninucleata. FEBS Lett 1991,
283:195–198.
18. Deva R, Ciccoli R, Kock JLF, Nigam S: Involvement of aspirin-sensitive
oxylipins in vulvovaginal candidiasis. FEMS Microbiol Lett 2001,
198:37–43.
19. Deva R, Ciccoli R, Schewe T, Kock JLF, Nigam S: Arachidonic acid
stimulates cell growth and forms a novel oxygenated metabolite in
Candida albicans. Biochim Biophys Acta 2000, 1486:299–311.
20. Ells R: The effect of arachidonic acid on lipid metabolism and biofilm
formation of two closely related Candida species.: Magister Scientiae
dissertation. University of the Free State, Department of Microbial,
Biochemical and Food Biotechnology; 2008.
21. Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB: Pathogenic
yeasts Cryptococcus neoformans and Candida albicans produce
immunomodulatory prostaglandins. Infect Immun 2001, 69:2957–2963.
22. Erb-Downward JR, Huffnagle GB: Cryptococcus neoformans produces
authentic prostaglandin E2 without a cyclooxygenase. Eukaryot Cell 2007,
6:346–350.
23. Erb-Downward JR, Noverr MC: Characterization of prostaglandin E2
production by Candida albicans. Infect Immun 2007, 75:3498–3505.
24. Noverr MC, Toews GB, Huffnagle GB: Production of prostaglandins and
leukotrienes by pathogenic fungi. Infect Immun 2002, 70:400–402.
25. Erb-Downward JR, Noggle RM, Williamson PR, Huffnagle GB: The role of
laccase in prostaglandin production by Cryptococcus neoformans. Mol
Microbiol 2008, 68:1428–1437.
Ells et al. Lipids in Health and Disease 2012, 11:100 Page 6 of 7
http://www.lipidworld.com/content/11/1/10026. Alem MAS, Douglas LJ: Effects of aspirin and other nonsteroidal anti-
inflammatory drugs on biofilms and planktonic cells of Candida albicans.
Antimicrob Agents Chemother 2004, 48:41–47.
27. Alem MAS, Douglas LJ: Prostaglandin production during growth of
Candida albicans biofilms. J Med Microbiol 2005, 54:1001–1005.
28. Segal E: Candida, still number one – what do we know and where are
we going from there? Mycoses 2005, 48:3–11.
29. Ells R, Kock JLF, Albertyn J, Kemp G, Pohl CH: Effect of inhibitors of
arachidonic acid metabolism on prostaglandin E2 production by Candida
albicans and Candida dubliniensis biofilms. Med Microbiol Immunol 2011,
200:23–28.
30. Shiraki Y, Ishibashi Y, Hiruma M, Nishikawa A, Ikeda S: Candida albicans
abrogates the expression of interferon-γ-inducible protein-10 in human
keratinocytes. FEMS Immunol Med Microbiol 2008, 54:122–128.
31. Biondo GA, Dias-Melicio LA, Bordon-Graciani AP, Acorci-Valério MJ, Soares
AMVC: Paracoccidioides brasiliensis uses endogenous and exogenous
arachidonic acid for PGEx production. Mycopathologia 2010, 170:123–130.
32. Bordon AP, Dias-Melicio LA, Acorci MJ, Biondo GA, Fecchio D, Peraçoli MTS,
Soares AMVC: Prostaglandin E2 production by high and low virulent
strains of Paracoccidioides brasiliensis. Mycopathologia 2007, 163:129–135.
33. Konturek SJ, Pawlik W: Physiology and pharmacology of prostaglandins.
Dig Dis Sci 1986, 31:6S–19S.
34. Yilmaz E: Biotechnological production of prostaglandin. Biotech Adv 2001,
19:387–397.
35. Brodhun F, Feussner I: Oxylipins in fungi. FEBS J 2011, 278:1047–1063.
36. Botha A, Kock JLF, Nigam S: The production of eicosanoid precursors by
mucoralean fungi. Adv Exp Med Biol 1997, 433:227–229.
37. Lamacka M, Sajbidor J: The content of prostaglandins and their
precursors in Mortierella and Cunninghamella species. Lett Appl Microbiol
1998, 26:224–226.
38. Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, Serhan CN,
Agabian N: Candida albicans modulates host defense by biosynthesizing
the pro-resolving mediator Resolvin E1. PLoS One 2007, 2:e1316.
39. Tsitsigiannis DI, Kowieski TM, Zarnowski R, Keller NP: Three putative
oxylipin biosynthetic genes integrate sexual and asexual development in
Aspergillus nidulans. Microbiology 2005, 151:1809–1821.
40. Park J, Lee S, Choi J, Ahn K, Park B, Park J, Kang S, Lee Y-H: Fungal
cytochrome P450 database. BMC Genomics 2008, 9:402.
41. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid
biology. Science 2001, 294:1871–1875.
42. Goodwin JS, Ceuppens J: Regulation of the immune response by
prostaglandins. J Clin Immunol 1983, 3:295–315.
43. Lamačka M, Šajbidor J: Biotechnological production of prostaglandins.
Appl Microbiol Biotechnol 1997, 47:199–206.
44. Hatae N, Sugimoto Y, Ichikawa A: Prostaglandin receptors: advances in
the study of EP3 receptor signaling. J Biochem 2002, 131:781–784.
45. Sornasse T, Larenas PV, Davis KA: deVries JE, Yssel H: Differentiation
and stability of T Helper 1 and 2 cells derived from naive human
neonatal CD4+T cells, analyzed at the single-cell level. J Exp Med
1996, 184:473–483.
46. Delves PJ, Roitt IM: The immune system. Second of two parts. N Engl J
Med 2000, 343:108–117.
47. van der Pouw Kraan TCTM, Boeije LCM, Smeenk RJT, Wijdenes J, Aarden LA:
Prostaglandin-E2 is a potent inhibitor of human interleukin 12
production. J Exp Med 1995, 181:775–779.
48. Shibata Y, Henriksen RA, Honda I, Nakamura RM, Myrvik QN: Splenic
PGE2-releasing macrophages regulate Th1 and Th2 immune responses
in mice treated with heat-killed BCG. J Leukoc Biol 2005, 78:1281–1290.
49. Betz M, Fox BS: Prostaglandin E2 inhibits production of Th1 lymphokines
but not of Th2 lymphokines. J Immunol 1991, 146:108–113.
50. Noverr MC, Erb-Downward JR, Huffnagle GB: Production of eicosanoids
and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev
2003, 16:517–533.
51. Romani L: Innate and adaptive immunity in Candida albicans infections
and saprophytism. J Leukoc Biol 2000, 68:175–179.
52. Santoni G, Boccanera M, Adriani D, Lucciarini R, Amantini C, Morrone S,
Cassone A, De Bernardis F: Immune cell-mediated protection against
vaginal candidiasis: Evidence for a major role of vaginal CD4+ T cells and
possible participation of other local lymphocyte effectors. Infect Immun
2002, 70:4791–4797.53. Schaller M, Mailhammer R, Korting HC: Cytokine expression induced by
Candida albicans in a model of cutaneous candidosis based on
reconstituted human epidermis. J Med Microbiol 2002, 51:672–676.
54. Cenci E, Mencacci A, Spaccapelo R, Tonnetti L, Mosci P, Enssle KH, Puccetti
P, Romani L, Bistoni F: T helper cell type 1 (Th1)- and Th2-like responses
are present in mice with gastric candidiasis but protective immunity is
associated with Th1 development. J Infect Dis 1995, 171:1279–1288.
55. Montagnoli C, Sandini S, Bacci A, Romani L, La Valle R: Immunogenicity
and protective effect of recombinant enolase of Candida albicans in a
murine model of systemic candidiasis. Med Mycol 2004, 42:319–324.
56. Romagnoli G, Nisini R, Chiani P, Mariotti S, Teloni R, Cassone A, Torosantucci
A: The interaction of human dendritic cells with yeast and germ-tube
forms of Candida albicans leads to efficient fungal processing, dendritic
cell maturation, and acquisition of a Th1 response-promoting function.
J Leukoc Biol 2004, 75:117–126.
57. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB: CCR2 expression
determines T1 versus T2 polarization during pulmonary Cryptococcus
neoformans infection. J Immunol 2000, 164:2021–2027.
58. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis
JL, Huffnagle GB, Toews GB, Olszewski MA: Cryptococcal urease promotes
the accumulation of immature dendritic cells and a non-protective T2
immune response within the lung. Am J Pathol 2009, 174:932–943.
59. Kundu G, Noverr MC: Exposure to host or fungal PGE2 abrogates
protection following immunization with Candida-pulsed dendritic cells.
Med Mycol 2011, 49:380–394.
60. Navarathna DHMLP, Nickerson KW, Duhamel GE, Jerrels TR, Petro TM:
Exogenous farnesol interferes with the normal progression of cytokine
expression during candidiasis in a mouse model. Infect Immun 2007,
75:4006–4011.
61. Smeekens SP, van de Veerdonk FL, van der Meer JWM, Kullberg BJ, Joosten
LAB, Netea MG: The Candida Th17 response is dependent on mannan-
and β-glucan-induced prostaglandin E2. Int Immunol 2010, 22:889–895.
62. Smeekens SP, van de Veerdonk FL, Joosten LAB, Jacobs L, Jansen T, Williams
DL, van der Meer JWM, Kullberg BJ, Netea MG: The classical CD14++ CD16-
monocytes, but not the patrolling CD14+ CD16+ monocytes, promote
Th17 responses to Candida albicans. Eur J Immunol 2011, 41:2915–2924.
63. Gagliardi MC, Teloni R, Mariotti S, Bromuro C, Chiani P, Romagnoli G,
Giannoni F, Torosantucci A, Nisini R: Endogenous PGE2 promotes the
induction of human Th17 responses by fungal β-glucan. J Leukoc Biol
2010, 88:947–954.
64. Noverr MC, Huffnagle GB: Regulation of Candida albicans morphogenesis
by fatty acid metabolites. Infect Immun 2004, 72:6206–6210.
65. Kalo-Klein A, Witkin SS: Prostaglandin E2 enhances and gamma interferon
inhibits germ tube formation in Candida albicans. Infect Immun 1990,
58:260–262.
66. Pelletier S, Dubé J, Villeneuve A, Gobeil F Jr, Yang Q, Battistini B, Guillemette
G, Sirois P: Prostaglandin E2 increases cyclic AMP and inhibits endothelin-
1 production/secretion by guinea-pig tracheal epithelial cells through
EP4 receptors. Br J Pharmacol 2001, 132:999–1008.
67. Rooney PJ, Klein BS: Linking fungal morphogenesis with virulence.
Cell Microbiol 2002, 4:127–137.
68. Ramage G, Saville SP, Thomas DP, López-Ribot JL: Candida biofilms: an
update. Eukaryot Cell 2005, 4:633–638.
69. Bhatt RK, Falck JR, Nigam S: Enantiospecific total synthesis of a novel
arachidonic acid metabolite 3-hydroxy eicosatetraenoic acid. Tet Lett
1998, 39:249–252.
70. Nigam S, Kumar SG, Kock JLF: Biological effects of 3-HETE, a novel
compound of the yeast Dipodascopsis uninucleata, on mammalian cells.
10th International Conference on Prostaglandins and Related Compounds,
Vienna, Austria. 1996.
71. Nigam S, Schewe T, Kock JLF: 3(R)-Hydroxy oxylipins-a novel family of
oxygenated polyenoic fatty acids of fungal origin. Adv Exp Med Biol 1999,
469:663–668.
72. Ciccoli R, Sahi S, Singh S, Prakash H, Zafiriou MP, Ishdorj G, Kock JLF, Nigam
S: Oxygenation by COX-2 (cyclo-oxygenase-2) of 3-HETE
(3-hydroxyeicosatetraenoic acid), a fungal mimetic of arachidonic acid,
produces a cascade of novel bioactive 3- hydroxyeicosanoids. J Biochem
2005, 390:737–747.
73. Deva R, Shankaranarayanan P, Ciccoli R, Nigam S: Candida albicans induces
selectively transcriptional activation of cyclooxygenase-2 in HeLa cells:
Ells et al. Lipids in Health and Disease 2012, 11:100 Page 7 of 7
http://www.lipidworld.com/content/11/1/100Pivotal roles of toll-like receptors, p38 mitogen-activated protein kinase,
and NF-κB. J Immunol 2003, 171:3047–3055.
74. Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs-differences and
similarities. Engl J Med 1991, 324:1716–1725.
75. Kock JLF, Sebolai OM, Pohl CH, van Wyk PWJ, Lodolo EJ: Oxylipin studies
expose aspirin as antifungal. FEMS Yeast Res 2007, 7:1207–1217.
76. Strong R, Miller RA, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA,
Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Harrison DE:
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically
heterogeneous male mice. Aging Cell 2008, 7:641–650.
77. de Quadros AU, Bini D, Pereira PAT, Moroni EG, Monteiro MC: Antifungal
activity of some cyclooxygenase inhibitors on Candida albicans:
PGE2-dependent mechanism. Folia Microbiol 2011, 56:349–352.
doi:10.1186/1476-511X-11-100
Cite this article as: Ells et al.: Arachidonic acid metabolites in
pathogenic yeasts. Lipids in Health and Disease 2012 11:100.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
